Status:
COMPLETED
Risperidone Augmentation for PTSD
Lead Sponsor:
Duke University
Collaborating Sponsors:
Janssen Pharmaceuticals
Conditions:
Post-Traumatic Stress Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to (1) compare the response of civilians with Posttraumatic Stress Disorder(PTSD) currently receiving sertraline without an optimal response to risperidone augmentation vs...
Detailed Description
This is a multi-center, two-phase study to evaluate the efficacy and safety of risperidone augmentation to sertraline treatment of Post-Traumatic Stress Disorder (PTSD). In the first phase, all patien...
Eligibility Criteria
Inclusion
- Signed consent prior to any study procedures being done
- Male or female outpatients between 18-65 years of age
- Trauma experienced meets trauma defined by DSM
- Meets criteria for DSM-IV PTSD as a result of civilian trauma
- CAPS Score of greater than or equal to 50 at screening and baseline
- Able to swallow whole capsules
- Fluency in both written and spoken English
- Negative urine drug screen at screening visit
- If female of childbearing potential, must have negative serum pregnancy test at screening visit and must agree to use a medically accepted means of contraception throughout the study and for 30 days after completion of the study
- To be include in Phase 2, must complete Phase I and must have less than 70% reduction from baseline on the CAPS
Exclusion
- Pregnant women or those likely to become pregnant, or nursing mothers
- Medical instability (clinically significant hepatic, cardiac, or pulmonary disease, HIV, uncontrolled hypertension, diabetes or thyroid conditions, seizure disorders, clinically significant laboratory abnormalities at screen
- Primary psychotic disorder, or history of schizophrenia, other psychotic disorder, bipolar disorder, or cognitive disorder
- Those considered a risk for suicidal or homicidal behavior (the clinician will immediately, upon assessing a risk for suicidal or homicidal behavior, refer the patient for further evaluation and probable hospitalization)
- Hypersensitivity or other contraindication to sertraline or risperidone
- Meeting DSM-IV criteria for drug or alcohol dependence within 3 months of study entry
- Those who are still experiencing an ongoing traumatic stressor (domestic violence/elder abuse) who will need to focus on safety (the clinician will make referrals as appropriate)
- DSM-IV primary diagnosis of any other anxiety disorder or major depressive disorder
- Current use of antipsychotic, or other psychotropic medications, or supplements with known psychotropic effects
- Current involvement in litigation related to PTSD
- Current psychotherapy aimed at treating PTSD
- PTSD as a result of combat-related trauma
- Previous failure to respond to sertraline-risperidone combination at therapeutic dose
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00215241
Start Date
April 1 2004
End Date
July 1 2006
Last Update
September 22 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University Medical Center
Atlanta, Georgia, United States, 30322
2
Medical University of South Carolina
Charleston, South Carolina, United States, 29425